Baseline ICIQ‐UI score, body mass index, age, average birth weight, and perineometry duration as promising predictors of the short‐term efficacy of Er:YAG laser treatment in stress urinary incontinent women: A prospective cohort study

Fistonić, Ivan; Fistonić, Nikola

doi:10.1002/lsm.22789

Cited by 34 publications

(36 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seventeen studies counting more than 892 female patients with UI were included in the review. 4,8,10,[14][15][16][17][18][19][20][21][22][23][24][25][26][27] The search of MEDLINE and SCOPUS provided a total of 878 records. After removing duplicates, 526 studies were excluded because they did not meet the criteria.…”

Section: Resultsmentioning

confidence: 99%

“…5(48.8-80) to 50(30-70) degrees. 18,22 Concerning the residual urine volume, in 2018, the same group observed an improvement from median volume of 2.9(0.8-9.4) at baseline to 0.5(0-1.7), 6 months after treatment.…”

Section: Perineometry and Urodynamicsmentioning

confidence: 86%

“…The sum-score may be divided into four severity categories: mild (1-5), moderate (6)(7)(8)(9)(10)(11)(12), severe (13)(14)(15)(16)(17)(18), and very severe (19-21) UI. 4,8,10,[17][18][19][20][21][22][23][24]27 Three studies used the and Overactive Bladder Questionnaire Short Form (OAB-Q SF), which consists of 19 items comprised by two scales: a 6-item Symptom Bother scale and a 13-item healthrelated quality of life (HRQOL) scale. 14,16,21,28 The Urogenital Distress Inventory (UDI-6) was used in 3 studies and the Incontinence Impact Questionnaire (IIQ-7) in 2 studies, with 6 and 7 questions regarding urinary incontinence, respectively.…”

Section: Patient Reported Outcomesmentioning

confidence: 99%

“…15 In 2018, the same group published a study which, besides the improvement in median ICIQ-UI SF score from 12 to 6 in the same period of time, points age, BMI, basal Q-tip and ICIQ-UI SF scores as predictors of greater improvement. 22 Tien et al 21 showed significant decrease, at 6 months follow-up, in OAB symptom score (4.1±2.8 to 2.7±2.6), UDI-6 (4.1±2.9 to 3.1±3.1), IIQ-7 score (3.2±4.2 to 2.7±4.9), PPBC score (2.7±1.0 to 2.0±1.1) and USS score (1.3±0.8 to 0.8±0.7). 14 Lin et al studied women with SUI alone or MUI and reported a mean decrease of 1, 1.2 and 1.8 in ICIQ-UI-SF, OAB symptom and UDI-6 scores, respectively, 3 months after treatment; but 12 months after there were no more statistically significant differences to baseline.…”

Section: Patient Reported Outcomesmentioning

confidence: 99%

See 3 more Smart Citations

Female urinary incontinence: is laser treatment effective? a systematic review

Br¹,

Ao²

2018

OGIJ

View full text Add to dashboard Cite

Background: Towards the recent promising results of microablative fractional CO 2 -laser and non-ablative photothermal Erbium: YAG-laser (Er:YAG-laser) as therapy performed in Gynaecology; this systematic review aims to summarize the effectiveness and safety of both laser technologies on female Urinary Incontinence (UI). Methods:Using "laser" and "urinary incontinence" as query, studies were searched from MEDLINE and SCOPUS up to February 2018. Information from seventeen studies, counting more than 892 female patients with UI, was systematically registered. 652 and more than 240 patients were treated with Er:YAG-laser and CO 2 -laser, respectively. Results:Results addressing patient reported outcomes through different validated questionnaires showed statistically significant improvement in UI after Laser therapy. Pad weight tests, perineometry, Q-tip test, urodynamics and epithelial biopsies as assessment to objective quantification of UI and pelvic structures remodeling also showed improvement but these results were not so consistent. In general, laser therapy was well tolerated and no major side effects were reported. Conclusion:Laser therapy seems to be a promising alternative approach to UI in women. However, there are no randomized controlled trials in this field and so the level of evidence is still low. More research is required to further apply these technologies in women safely and effectively.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Perineometry and Urodynamicsmentioning

confidence: 86%

Section: Patient Reported Outcomesmentioning

confidence: 99%

Section: Patient Reported Outcomesmentioning

confidence: 99%

See 2 more Smart Citations

Female urinary incontinence: is laser treatment effective? a systematic review

Br¹,

Ao²

2018

OGIJ

View full text Add to dashboard Cite

show abstract

“…In human soft tissue, the 2940 nm erbium yttrium‐aluminum‐garnet medium (Er:YAG) laser in the non‐ablative thermal mode has been shown to stimulate deep collagen remodeling and improve tightness and elasticity of the treated area . This non‐ablative treatment modality has been evaluated in several studies . A study evaluating Er:YAG laser treatment compared with topical estrogen therapy for GSM‐related symptoms demonstrated greater improvement in symptoms (irritation, dyspareunia, dryness, chronic leukorrhea) of the laser‐treated group up to 18 months of follow‐up after treatment.…”

Section: Discussionmentioning

confidence: 99%

Lasers and energy‐based devices marketed for vaginal rejuvenation: A cross‐sectional analysis of the MAUDE database

2019

View full text Add to dashboard Cite

Introduction:The FDA issued a statement on July 30, 2018, expressing concern over the marketing of lasers and energy-based devices to promote "vaginal rejuvenation." The FDA stated that there is insufficient data to recommend this modality for optimization of sexual function and alleviation of genitourinary syndrome of menopause (GSM)-related symptoms in postmenopausal or postpartum women. This analysis aims to characterize the mandatory and voluntary reports concerning laser and energy-based procedures marketed for vaginal rejuvenation. Methods: Cross-sectional analysis of the FDA database, Manufacturer and User Facility Device Experience (MAUDE), for events related to laser and energy-based devices for vaginal rejuvenation. Results: Between October 2015 and January 2019, 45 distinct events describing 46 patients were recorded and reviewed. The most commonly reported adverse event related to the procedure was pain (vulvar, bladder, urethral, or unspecified) (n ¼ 19). The majority of patients sought medical care for their injuries, which included evaluation by urgent care, urology, gynecology, neurology, gastroenterology, pelvic floor therapy, primary care providers, and the device operator. Thirtythree patients indicated chronicity of their injury, which included long-term pain, numbness, burning, bladder disturbances, infections, scarring, dyspareunia, worsening symptoms, aggravation of lichen sclerosis, and disfigurement. Conclusions: A variety of adverse events associated with the use of laser and energy-based devices for "vaginal rejuvenation" was reported to the MAUDE database. Although the circumstances surrounding these events were unclear, these reports signify the importance of clinical trials that investigate the efficacy and safety profile of laser and energy-based devices for optimization of sexual function and treatment of GSM-related symptoms. Lasers Surg. Med.

show abstract

Vaginal erbium laser treatment for stress urinary incontinence: A multicenter randomized sham‐controlled clinical trial

O'Reilly,

Viereck,

Phillips

et al. 2023

Intl J Gynecology & Obste

View full text Add to dashboard Cite

ObjectiveTo evaluate the efficacy and safety of non‐ablative vaginal Er:YAG laser device in stress urinary incontinence (SUI) treatment.MethodsWe conducted a multicenter blinded randomized sham‐controlled trial in which women with urodynamic SUI were randomization to active arm using Er:YAG laser therapy, and sham arm using sham handpiece. Patients received two treatments 1 month apart. The primary outcomes measure was 1 h pad weight test measured at 6 months. Secondary outcomes were durability of treatment success at 12 months, and questionnaires for assessment of SUI severity (ICIQ‐UI SF), sexual function (PISQ‐12) and HRQoL (KHQ), and incidence and severity of device related adverse events and pain (VAS).ResultsA total of 110 participants with SUI were recruited; 73 in the active arm and 37 in the sham arm. Two participants were excluded; one was assigned the wrong treatment and one withdrew their consent. Treatment success was observed in 36% of the sham arm and 59% of the active arm; in the latter, odds of achieving treatment success were more than three‐fold higher (OR 3.63, 95% CI: 1.3–11.2, P = 0.02). HRQoL by KHQ showed significant improvement in the active versus the sham arm (OR 0.36, 95% CI: 0.15–0.87, P = 0.003). Similarly, subjective patient assessment of general and sexual function improvement with PISQ‐12 and PGI‐I showed superior effect over sham (OR 2.8, 95% CI: 1.2–7.0, P = 0.02 and OR 0.13, 95% CI: 0.05–0.36, P < 0.001, respectively).ConclusionNon‐ablative vaginal Er:YAG laser therapy significantly improves SUI symptoms versus sham treatment. Er:YAG laser therapy should be considered as a non‐surgical treatment option for SUI patients.

show abstract

Baseline ICIQ‐UI score, body mass index, age, average birth weight, and perineometry duration as promising predictors of the short‐term efficacy of Er:YAG laser treatment in stress urinary incontinent women: A prospective cohort study

Cited by 34 publications

References 33 publications

Female urinary incontinence: is laser treatment effective? a systematic review

Female urinary incontinence: is laser treatment effective? a systematic review

Lasers and energy‐based devices marketed for vaginal rejuvenation: A cross‐sectional analysis of the MAUDE database

Vaginal erbium laser treatment for stress urinary incontinence: A multicenter randomized sham‐controlled clinical trial

Contact Info

Product

Resources

About